CDK6, a new target in MLL-driven leukemia

Iléana Antony-Debré; Ulrich Steidl

doi:10.1182/blood-2014-05-572917

CDK6, a new target in MLL-driven leukemia

Iléana Antony-Debré, Ulrich Steidl

Cell Biology

Research output: Contribution to journal › Review article › peer-review

9 Scopus citations

Abstract

In this issue of Blood, Placke et al identify the cell-cycle regulator CDK6 as a promising new target in mixed lineage leukemia (MLL)-rearranged acute myeloid leukemia (AML) and show that its downregulation or pharmacological inhibition leads to growth inhibition and differentiation of MLL-driven leukemic cells.

Original language	English (US)
Pages (from-to)	5-6
Number of pages	2
Journal	Blood
Volume	124
Issue number	1
DOIs	https://doi.org/10.1182/blood-2014-05-572917
State	Published - Jul 3 2014

ASJC Scopus subject areas

Biochemistry
Immunology
Hematology
Cell Biology

Access to Document

10.1182/blood-2014-05-572917

Cite this

@article{2a1adcdc0cdc4cefa65968daf9487500,

title = "CDK6, a new target in MLL-driven leukemia",

abstract = "In this issue of Blood, Placke et al identify the cell-cycle regulator CDK6 as a promising new target in mixed lineage leukemia (MLL)-rearranged acute myeloid leukemia (AML) and show that its downregulation or pharmacological inhibition leads to growth inhibition and differentiation of MLL-driven leukemic cells.",

author = "Il{\'e}ana Antony-Debr{\'e} and Ulrich Steidl",

year = "2014",

month = jul,

day = "3",

doi = "10.1182/blood-2014-05-572917",

language = "English (US)",

volume = "124",

pages = "5--6",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "1",

}

TY - JOUR

T1 - CDK6, a new target in MLL-driven leukemia

AU - Antony-Debré, Iléana

AU - Steidl, Ulrich

PY - 2014/7/3

Y1 - 2014/7/3

N2 - In this issue of Blood, Placke et al identify the cell-cycle regulator CDK6 as a promising new target in mixed lineage leukemia (MLL)-rearranged acute myeloid leukemia (AML) and show that its downregulation or pharmacological inhibition leads to growth inhibition and differentiation of MLL-driven leukemic cells.

AB - In this issue of Blood, Placke et al identify the cell-cycle regulator CDK6 as a promising new target in mixed lineage leukemia (MLL)-rearranged acute myeloid leukemia (AML) and show that its downregulation or pharmacological inhibition leads to growth inhibition and differentiation of MLL-driven leukemic cells.

UR - http://www.scopus.com/inward/record.url?scp=84904012909&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904012909&partnerID=8YFLogxK

U2 - 10.1182/blood-2014-05-572917

DO - 10.1182/blood-2014-05-572917

M3 - Review article

C2 - 24993876

AN - SCOPUS:84904012909

SN - 0006-4971

VL - 124

SP - 5

EP - 6

JO - Blood

JF - Blood

IS - 1

ER -

CDK6, a new target in MLL-driven leukemia

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this